Header Logo

Connection

WOLFGANG WINKELMAYER to Renal Insufficiency, Chronic

Back to Details
This is a "connection" page, showing publications WOLFGANG WINKELMAYER has written about Renal Insufficiency, Chronic.
WOLFGANG WINKELMAYER
Connection Strength
13.374
Renal Insufficiency, Chronic
  1. Cardiovascular Safety of Roxadustat in CKD Anemia: A Fig Leaf Named Noninferiority. Clin J Am Soc Nephrol. 2021 08; 16(8):1155-1157.
    View in: PubMed
    Score: 0.420
  2. Black Race Coefficient in GFR Estimation and Prevalence of CKD-Related Complications. Clin J Am Soc Nephrol. 2021 10; 16(10):1562-1564.
    View in: PubMed
    Score: 0.416
  3. Black Race Coefficient in GFR Estimation and Diabetes Medications in CKD: National Estimates. J Am Soc Nephrol. 2021 06 01; 32(6):1319-1321.
    View in: PubMed
    Score: 0.411
  4. Sex differences in chronic kidney disease awareness among US adults, 1999 to 2018. PLoS One. 2020; 15(12):e0243431.
    View in: PubMed
    Score: 0.402
  5. Direct oral anticoagulants in chronic kidney disease: an update. Curr Opin Nephrol Hypertens. 2020 09; 29(5):489-496.
    View in: PubMed
    Score: 0.394
  6. Patient and Caregiver Perspectives on Terms Used to Describe Kidney Health. Clin J Am Soc Nephrol. 2020 07 01; 15(7):937-948.
    View in: PubMed
    Score: 0.389
  7. Mapping Progress in Reducing Cardiovascular Risk with Kidney Disease: Atrial Fibrillation. Clin J Am Soc Nephrol. 2018 09 07; 13(9):1423-1425.
    View in: PubMed
    Score: 0.342
  8. Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study. BMC Nephrol. 2017 Jun 17; 18(1):196.
    View in: PubMed
    Score: 0.315
  9. Worldwide Preparedness for Kidney Health Care. JAMA. 2017 05 09; 317(18):1838-1839.
    View in: PubMed
    Score: 0.313
  10. Reduced risk of myocardial infarct and revascularization following coronary artery bypass grafting compared with percutaneous coronary intervention in patients with chronic kidney disease. Kidney Int. 2016 08; 90(2):411-421.
    View in: PubMed
    Score: 0.293
  11. Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients. Nephrol Dial Transplant. 2015 Dec; 30(12):2068-75.
    View in: PubMed
    Score: 0.278
  12. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study. Am J Kidney Dis. 2015 Jul; 66(1):106-13.
    View in: PubMed
    Score: 0.272
  13. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis. Am J Kidney Dis. 2015 Jul; 66(1):69-74.
    View in: PubMed
    Score: 0.267
  14. Perspectives on pregnancy in women with chronic kidney disease: systematic review of qualitative studies. Nephrol Dial Transplant. 2015 Apr; 30(4):652-61.
    View in: PubMed
    Score: 0.265
  15. Use of novel oral anticoagulants in patients with end-stage renal disease. Hemodial Int. 2015 Jan; 19(1):150-3.
    View in: PubMed
    Score: 0.265
  16. Review: In CKD, novel oral anticoagulants do not differ from vitamin K antagonists for efficacy or bleeding. Ann Intern Med. 2014 Sep 16; 161(6):JC10.
    View in: PubMed
    Score: 0.261
  17. Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010). JAMA Intern Med. 2014 May; 174(5):699-707.
    View in: PubMed
    Score: 0.254
  18. Warfarin treatment in patients with atrial fibrillation and advanced chronic kidney disease: sins of omission or commission? JAMA. 2014 Mar 05; 311(9):913-5.
    View in: PubMed
    Score: 0.251
  19. IV iron dosing regimens: choice of agent and dosing frequency. Nephrol News Issues. 2014 Feb; 28(2):10-1, 18.
    View in: PubMed
    Score: 0.250
  20. Thematic synthesis of qualitative studies on patient and caregiver perspectives on end-of-life care in CKD. Am J Kidney Dis. 2014 Jun; 63(6):913-27.
    View in: PubMed
    Score: 0.248
  21. Use and safety of heparin-free maintenance hemodialysis in the USA. Nephrol Dial Transplant. 2013 Jun; 28(6):1589-602.
    View in: PubMed
    Score: 0.236
  22. More evidence on an abominable pairing: atrial fibrillation and kidney disease. Circulation. 2013 Feb 05; 127(5):560-2.
    View in: PubMed
    Score: 0.233
  23. Predialyis nephrology care of older individuals approaching end-stage renal disease. Semin Dial. 2012 Nov-Dec; 25(6):628-32.
    View in: PubMed
    Score: 0.229
  24. What caused excess strokes in patients randomized to darbepoetin in the trial to reduce cardiovascular events with Aranesp therapy (TREAT)?: no smoking gun. Circulation. 2011 Dec 20; 124(25):2805-8.
    View in: PubMed
    Score: 0.216
  25. Chronic on acute renal failure: long-term implications of severe acute kidney injury. JAMA. 2009 Sep 16; 302(11):1227-9.
    View in: PubMed
    Score: 0.184
  26. Lessons from geographic variations in predialysis nephrology care. J Am Soc Nephrol. 2009 May; 20(5):930-2.
    View in: PubMed
    Score: 0.179
  27. Disease activity of rheumatoid arthritis and kidney function decline: a large prospective registry study. Ann Rheum Dis. 2025 Feb; 84(2):201-209.
    View in: PubMed
    Score: 0.133
  28. Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis. Nephrol Dial Transplant. 2023 09 29; 38(10):2358-2367.
    View in: PubMed
    Score: 0.122
  29. Trends and perspectives for improving quality of chronic kidney disease care: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2023 11; 104(5):888-903.
    View in: PubMed
    Score: 0.119
  30. Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2023 10; 104(4):655-680.
    View in: PubMed
    Score: 0.119
  31. Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials. Am J Nephrol. 2022; 53(10):701-710.
    View in: PubMed
    Score: 0.115
  32. Diseases of the Aorta and Kidney Disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Cardiovasc Res. 2022 09 20; 118(12):2582-2595.
    View in: PubMed
    Score: 0.114
  33. Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease. Am J Hematol. 2022 09; 97(9):1178-1188.
    View in: PubMed
    Score: 0.112
  34. Child and caregiver perspectives on access to psychosocial and educational support in pediatric chronic kidney disease: a focus group study. Pediatr Nephrol. 2023 01; 38(1):249-260.
    View in: PubMed
    Score: 0.110
  35. Cardiovascular outcomes associated with prescription of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with diabetes and chronic kidney disease. Diabetes Obes Metab. 2022 05; 24(5):928-937.
    View in: PubMed
    Score: 0.109
  36. Updated US Prevalence Estimates for Chronic Kidney Disease Stage and Complications Using the New Race-Free Equation to Estimate Glomerular Filtration Rate. JAMA Netw Open. 2022 02 01; 5(2):e220460.
    View in: PubMed
    Score: 0.109
  37. Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrol Dial Transplant. 2021 11 09; 36(11):2039-2048.
    View in: PubMed
    Score: 0.107
  38. Renin-angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease. Nephrol Dial Transplant. 2021 09 27; 36(10):1893-1899.
    View in: PubMed
    Score: 0.106
  39. Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney Int. 2021 09; 100(3):516-526.
    View in: PubMed
    Score: 0.104
  40. Central and peripheral arterial diseases in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2021 07; 100(1):35-48.
    View in: PubMed
    Score: 0.103
  41. Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. N Engl J Med. 2021 04 29; 384(17):1589-1600.
    View in: PubMed
    Score: 0.103
  42. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 04 29; 384(17):1601-1612.
    View in: PubMed
    Score: 0.103
  43. Mortality, Kidney Failure, and Hospitalization Among Medicare Beneficiaries With CKD and Pulmonary Hypertension. Am J Kidney Dis. 2021 11; 78(5):700-708.e1.
    View in: PubMed
    Score: 0.103
  44. Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney Int. 2021 06; 99(6):1280-1295.
    View in: PubMed
    Score: 0.103
  45. Association of Blood Pressure Variability and Diuretics With Cardiovascular Events in Patients With Chronic Kidney Disease Stages 1-5. Hypertension. 2021 03 03; 77(3):948-959.
    View in: PubMed
    Score: 0.101
  46. Prevalence, correlates and outcomes of absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease. Nephrol Dial Transplant. 2021 01 01; 36(1):129-136.
    View in: PubMed
    Score: 0.101
  47. Nomenclature for kidney function and disease-executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference. Eur Heart J. 2020 12 21; 41(48):4592-4598.
    View in: PubMed
    Score: 0.101
  48. KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. Kidney Int. 2020 12; 98(6):1407-1418.
    View in: PubMed
    Score: 0.100
  49. KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and?managing kidney cancer. Kidney Int. 2020 11; 98(5):1108-1119.
    View in: PubMed
    Score: 0.100
  50. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics. Am Heart J. 2021 05; 235:1-11.
    View in: PubMed
    Score: 0.100
  51. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2021 01; 99(1):34-47.
    View in: PubMed
    Score: 0.100
  52. Patient and Caregiver Priorities for Outcomes in CKD: A Multinational Nominal Group Technique Study. Am J Kidney Dis. 2020 11; 76(5):679-689.
    View in: PubMed
    Score: 0.097
  53. [Hospitalization and Critical Illness in Chronic Kidney Disease]. Cardiorenal Med. 2020; 10(5):302-312.
    View in: PubMed
    Score: 0.096
  54. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney Int. 2020 06; 97(6):1117-1129.
    View in: PubMed
    Score: 0.095
  55. Association between intensity of statin therapy and mortality in persons with chronic kidney disease. Nephrol Dial Transplant. 2020 02 01; 35(2):312-319.
    View in: PubMed
    Score: 0.095
  56. Chronic Kidney Disease and Coronary?Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 10 08; 74(14):1823-1838.
    View in: PubMed
    Score: 0.093
  57. Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019 10; 96(4):836-849.
    View in: PubMed
    Score: 0.092
  58. Antidiabetic medication use in patients with type 2 diabetes and chronic kidney disease. J Diabetes Complications. 2019 11; 33(11):107423.
    View in: PubMed
    Score: 0.092
  59. Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019 05; 95(5):1027-1036.
    View in: PubMed
    Score: 0.090
  60. Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019 06; 95(6):1304-1317.
    View in: PubMed
    Score: 0.090
  61. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review. J Med Econ. 2019 Jun; 22(6):593-604.
    View in: PubMed
    Score: 0.089
  62. Identifying Important Outcomes for Young People With CKD and Their Caregivers: A Nominal Group Technique Study. Am J Kidney Dis. 2019 07; 74(1):82-94.
    View in: PubMed
    Score: 0.089
  63. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019 02; 95(2):268-280.
    View in: PubMed
    Score: 0.088
  64. Facility-Level Variations in Kidney Disease Care among Veterans with Diabetes and CKD. Clin J Am Soc Nephrol. 2018 12 07; 13(12):1842-1850.
    View in: PubMed
    Score: 0.087
  65. Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop. Kidney Int. 2018 12; 94(6):1053-1068.
    View in: PubMed
    Score: 0.087
  66. Cause-Specific Mortality in Patients with Chronic Kidney Disease and Atrial Fibrillation. Am J Nephrol. 2018; 48(1):36-45.
    View in: PubMed
    Score: 0.085
  67. Child and Parental Perspectives on Communication and Decision Making in Pediatric CKD: A Focus Group Study. Am J Kidney Dis. 2018 10; 72(4):547-559.
    View in: PubMed
    Score: 0.085
  68. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J. 2018 06 21; 39(24):2314-2325.
    View in: PubMed
    Score: 0.085
  69. Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a?Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2018 06; 93(6):1281-1292.
    View in: PubMed
    Score: 0.083
  70. High-density lipoprotein cholesterol and causes of death in chronic kidney disease. J Clin Lipidol. 2018 Jul - Aug; 12(4):1061-1071.e7.
    View in: PubMed
    Score: 0.083
  71. Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving?Global Outcomes (KDIGO) Controversies?Conference. Kidney Int. 2018 03; 93(3):545-559.
    View in: PubMed
    Score: 0.082
  72. Treating Depression in Patients With Advanced CKD: Beyond the Generalizability Frontier. JAMA. 2017 11 21; 318(19):1873-1874.
    View in: PubMed
    Score: 0.081
  73. Patterns of NSAIDs Use and Their Association with Other Analgesic Use in CKD. Clin J Am Soc Nephrol. 2017 Nov 07; 12(11):1778-1786.
    View in: PubMed
    Score: 0.080
  74. Blood pressure parameters are associated with all-cause and cause-specific mortality in chronic kidney disease. Kidney Int. 2017 11; 92(5):1272-1281.
    View in: PubMed
    Score: 0.079
  75. Diabetes Control and the Risks of ESRD and Mortality in?Patients?With CKD. Am J Kidney Dis. 2017 Aug; 70(2):191-198.
    View in: PubMed
    Score: 0.077
  76. Warfarin Initiation, Atrial Fibrillation, and Kidney Function:?Comparative Effectiveness and Safety of?Warfarin?in?Older?Adults?With Newly Diagnosed Atrial?Fibrillation. Am J Kidney Dis. 2017 Jun; 69(6):734-743.
    View in: PubMed
    Score: 0.076
  77. Safety and Clinical Outcomes of Catheter Ablation of Atrial Fibrillation in Patients With Chronic Kidney Disease. J Cardiovasc Electrophysiol. 2017 01; 28(1):39-48.
    View in: PubMed
    Score: 0.076
  78. Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. Heart. 2017 06; 103(11):818-826.
    View in: PubMed
    Score: 0.076
  79. Standardised Outcomes in Nephrology-Children and Adolescents (SONG-Kids): a protocol for establishing a core outcome set for children with chronic kidney disease. Trials. 2016 08 12; 17:401.
    View in: PubMed
    Score: 0.074
  80. Obstructive and Restrictive Lung Function Measures and CKD: National Health and Nutrition Examination Survey (NHANES) 2007-2012. Am J Kidney Dis. 2016 09; 68(3):414-21.
    View in: PubMed
    Score: 0.073
  81. Patient and Caregiver Priorities for Outcomes in Hemodialysis: An International Nominal Group Technique Study. Am J Kidney Dis. 2016 Sep; 68(3):444-54.
    View in: PubMed
    Score: 0.072
  82. Perspectives on Pregnancy in Women With CKD: A Semistructured Interview Study. Am J Kidney Dis. 2015 Dec; 66(6):951-61.
    View in: PubMed
    Score: 0.070
  83. Menopausal symptoms in women with chronic kidney disease. Menopause. 2015 Sep; 22(9):1006-11.
    View in: PubMed
    Score: 0.070
  84. Standardised outcomes in nephrology - Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis. Trials. 2015 Aug 19; 16:364.
    View in: PubMed
    Score: 0.069
  85. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. BMJ. 2015 Feb 03; 350:h246.
    View in: PubMed
    Score: 0.067
  86. Patients' perspectives on hemodialysis vascular access: a systematic review of qualitative studies. Am J Kidney Dis. 2014 Dec; 64(6):937-53.
    View in: PubMed
    Score: 0.065
  87. Qualitative research in CKD: an overview of methods and applications. Am J Kidney Dis. 2014 Sep; 64(3):338-46.
    View in: PubMed
    Score: 0.063
  88. A randomized, double-blind, placebo-controlled trial of calcium acetate on serum phosphorus concentrations in patients with advanced non-dialysis-dependent chronic kidney disease. BMC Nephrol. 2011 Feb 16; 12:9.
    View in: PubMed
    Score: 0.051
  89. Nomenclature for Kidney Function and Disease: Executive Summary and Glossary From a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Am J Kidney Dis. 2020 08; 76(2):157-160.
    View in: PubMed
    Score: 0.024
  90. Hospitalizations and Nursing Facility Stays During the Transition from CKD to ESRD on Dialysis: An Observational Study. J Gen Intern Med. 2017 Nov; 32(11):1220-1227.
    View in: PubMed
    Score: 0.020
  91. Antihypertensive Medication Use in Older Patients Transitioning from Chronic Kidney Disease to End-Stage Renal Disease on Dialysis. Clin J Am Soc Nephrol. 2016 08 08; 11(8):1401-1412.
    View in: PubMed
    Score: 0.018
  92. Research priority setting in kidney disease: a systematic review. Am J Kidney Dis. 2015 May; 65(5):674-83.
    View in: PubMed
    Score: 0.017
  93. Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients. Clin Nephrol. 2012 Sep; 78(3):181-8.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.